25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?

Support Care Cancer 2018 Aug 6;26(8):2825-2832. Epub 2018 Mar 6.

General Surgery Unit, Stanley Dudrick's Memorial Hospital, 15 Tyniecka Street, 32-050, Skawina, Poland.

Introduction: Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies.

Methodology: Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics.

Results: There were 37 (27.8%) patients with the severe 25(OH)D deficiency ≤ 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D < 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529).

Conclusion: The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D < 19.6 nmol/l had a significantly shorter PFS.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-018-4101-9DOI Listing
August 2018
58 Reads
1 Citation
2.364 Impact Factor

Publication Analysis

Top Keywords

25ohd deficiency
12
patients lymphoid
8
prevalence significance
8
25ohd
5
patients
5
patients desired
4
age 18-84
4
median 1-32
4
18-84 years
4
years untreated
4
malignancy chemiluminescent
4
pfs median
4
chemiluminescent immunoassay
4
insufficiency 50-75 nmol/l
4
lymphoid malignancy
4
untreated patients
4
50-75 nmol/l patients
4
rank statisticsresults
4
men median
4
belgrade pretreatment
4

References

(Supplied by CrossRef)

D Gupta et al.
Exp Ther Med 2011

D Bikle et al.
J Clin Endocrinol Metab 2009

MT Drake et al.
J Clin Oncol 2010

S Nagpal et al.
Endocr Rev 2005

BW Hollis et al.
Nutr Rev 2007

S Tretli et al.
Cancer Causes Control 2012

R Chowdhury et al.
BMJ 2014

J Bittenbring et al.
J Clin Oncol 2014

E Campo et al.
Blood 2011

J Sorennsens et al.
Br J Cancer 1993

SA Rosenberg et al.
Cancer Treat Rep 1977

Similar Publications